Court Rejects FTC Decision, Backs Schering
- Share via
An appeals court sided with Schering-Plough Corp., rejecting a finding by U.S. antitrust enforcers that the company illegally kept less expensive versions of the high blood pressure drug K-Dur off the market.
A three-judge panel of the U.S. 11th Circuit Court of Appeals in Atlanta on Tuesday rejected a 2003 Federal Trade Commission ruling that Schering-Plough’s settlements of patent suits with Upsher-Smith Laboratories Inc. and American Home Products, now Wyeth, amounted to payoffs to keep them out of the market.
Stephen Galpin, a spokesman for Kenilworth, N.J.-based Schering-Plough, said company executives “were gratified that the Court of Appeals saw the case as we did.”
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
